Jazz Pharmaceuticals Gets UK Approval for Biliary Tract Cancer Treatment
MT Newswires Live
Feb 19
Jazz Pharmaceuticals (JAZZ) Research UK has obtained approval for zanidatamab from the UK's Medicines and Healthcare products Regulatory Agency to treat biliary tract cancer in adults, the agency said Thursday.
The drug is approved for use in adults with cancer with high levels of HER2 protein that has progressed after previous treatment, the agency said.
The approval was given based on a study showing that cancer shrank or was no longer detectable in 52% of treated patients after an average follow-up of 34 months, the agency said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.